SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Amendment No. 1
Under the Securities Exchange Act of 1934
ILEX Oncology, Inc.
--------------------
(Name of Issuer)
Common Stock
--------------------
(Title of Class of Securities)
451923106
--------------------
(CUSIP Number)
Hilary Strain
One Embarcadero Center, Suite 4050
San Francisco CA 94111
(415) 362-4022
---------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
February 23, 2000
---------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box
[ ].
Check the following box if a fee is being paid with this statement [ ].
(A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent of
the class of securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent or less of
such class. (See Rule 13d-7).
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom copies
are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act") or otherwise subject to the
liabilities of that section of the Exchange Act but shall be subject to all
other provisions of the Exchange Act.
(Continued on following page(s))
Page 1 of 18 Pages
<PAGE>
CUSIP No. 000451923106 13D Page 2 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Alta Partners
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b))X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
California
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0-
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
-0-
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IA
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 3 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Alta BioPharma Partners, L.P.
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b))X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
Delaware
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0-
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
-0-
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
PN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 4 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Alta Embarcadero BioPharma, LLC
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b))X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
California
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0-
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
-0-
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 5 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
ILEX Chase Partners (Alta Bio), LLC
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b))X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
Delaware
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0-
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
-0-
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 6 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Alta BioPharma Management, LLC
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b))X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
Delaware
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0-
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
-0-
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 7 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Alta/Chase BioPharma Management, LLC
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b))X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
WC
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
Delaware
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power -0-
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power -0-
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
-0-
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
-0-
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 8 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Jean Deleage
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b)X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power 17,340
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power 17,340
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
17,340
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0.08%
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 9 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Garrett Gruener
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b)X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power 28,295
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power 28,295
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
28,295
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0.13%
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 10 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Daniel Janney
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b)X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power 38,108
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power 38,108
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
38,108
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0.18%
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 11 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Alix Marduel
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b)X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power 38,108
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power 38,108
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
38,108
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0.18%
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 12 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Guy Nohra
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b)X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power 27,945
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power 27,945
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
27,945
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0.13%
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 000451923106 13D Page 13 of 18 Pages
- --------------------------------------------------------------------------------
(1) Names of Reporting Persons. SS or I.R.S. Identification Nos.of Above Persons
Marino Polestra
- --------------------------------------------------------------------------------
(2) Check The Appropriate Box If A Member Of A Group (a):
(b)X
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source Of Funds*
AF
- --------------------------------------------------------------------------------
(5) Check Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items
2(d) Or 2(e):
- --------------------------------------------------------------------------------
(6) Citizenship Or Place Of Organization
U.S.A.
- --------------------------------------------------------------------------------
Number Of Shares (7) Sole Voting Power 27,945
Beneficially Owned
By Each Reporting
Person With (8) Shared Voting Power -0-
(9) Sole Dispositive Power 27,945
(10) Shared Dispositive Power -0-
(11) Aggregate Amount Beneficially Owned By Each Reporting Person
27,945
- --------------------------------------------------------------------------------
(12) Check If The Aggregate Amount In Row (11) Excludes Certain Shares*
- --------------------------------------------------------------------------------
(13) Percent Of Class Represented By Amount In Row (11)
0.13%
- --------------------------------------------------------------------------------
(14) Type Of Reporting Person
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
Item 1. Security and Issuer.
This Statement on Schedule D relates to the Common Stock,
$0.01 par value per share (the "Shares"), of ILEX Corporation, a Delaware
corporation (the "Company"). The principal executive offices of the Company are
located at 11550 IH-10 West, Suite 300, San Antonio TX 78230-1064.
Item 2. Identity and Background.
(a) This Statement is filed by Alta BioPharma Partners, L.P.,
a Delaware limited partnership ("Alta BioPharma"), and Alta Embarcadero
BioPharma, LLC, a California limited liability company ("Embarcadero LLC"), and
ILEX Chase Partners (Alta Bio), LLC, a Delaware LLC ("ILEX Alta Bio") by virtue
of their direct beneficial ownership of Shares, by Alta BioPharma Management
Partners, LLC, a Delaware limited liability company ("Alta Management"), by
virtue of being the sole general partner of Alta BioPharma, by Alta/Chase
BioPharma Management LLC, a Delaware limited liability company (Alta/Chase
Management) by virtue of being the sole managing director of ILEX Alta Bio and
by Alta Partners, a California corporation ("Alta Partners"), by virtue of being
the management advisory company of these entities. Alta BioPharma, Embarcadero
LLC, ILEX Alta Bio, Alta Management, Alta/Chase Management and Alta Partners are
collectively referred to as the "Reporting Persons." Jean Deleage, Garrett
Gruener, Dan Janney, Alix Marduel, Guy Nohra and Marino Polestra (the
"Partners") are the managing directors of Alta Management, Alta/Chase Management
and officers of Alta Partners. By virtue of the relationships described above
and their roles with Alta Partners, each of the Partners may be deemed to
control Alta Partners, Alta/Chase Management, Alta Management, and, therefore,
may be deemed to possess indirect beneficial ownership of the Shares held by
each entity. However, none of the Partners, acting alone, has voting or
investment power with respect to the Shares directly beneficially held by the
entities and, as a result, the Partners disclaim beneficial ownership of the
Shares directly beneficially owned by each entity, except to the extent of their
pecuniary interest in each entity. Embarcadero LLC is a side company that makes
all investments pro rata to the capital of Alta BioPharma with all allocations
made to its members based on paid-in capital. Certain of the Partners are
members of Embarcadero LLC and certain members of Embarcadero LLC are affiliates
of Alta Partners.
(b) The principal executive offices of Alta BioPharma,
Embarcadero LLC, ILEX Alta Bio, Alta Management, Alta/Chase Management and Alta
Partners, and the business address of each Partner, are located at One
Embarcadero Center, Suite 4050, San Francisco, California 94111.
(c) Alta Partners provides investment advisory services to
venture capital firms. Alta BioPharma, ILEX Alta Bio and Embarcadero LLC's
principal business is acting as venture capital investment vehicles. Alta/Chase
Management and Alta Management's principal business is acting as managing
director of ILEX Alta Bio and Alta BioPharma, respectively. Each of the
Partners' principal business is acting as a managing director of Alta Management
and Alta/Chase Management and as an officer of Alta Partners.
(d) None of the Reporting Persons or, to the knowledge of the
Reporting Persons, any of the Partners, has been convicted in a criminal
proceeding in the past five years (excluding traffic violations or similar
misdemeanors).
(e) During the past five years, none of the Reporting Persons
or, to the knowledge of the Reporting Persons, and none of the Partners, was a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction as a result of which such person was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws of finding any
violation with respect to such laws.
<PAGE>
(f) Alta Partners is a California corporation. Alta BioPharma
is a Delaware limited partnership. Embarcadero LLC is a California limited
liability corporation. ILEX Alta Bio is a Delaware limited liability company.
Alta Management and Alta/Chase Management are Delaware limited liability
companies. Each of the Partners is a citizen of the United States.
Item 3. Source and Amount of Funds or Other Consideration.
The total amount of funds required by Alta BioPharma to
acquire the 742,547 shares of Common Stock reported in Item 5(a) was
$6,215,859.00, the total amount of funds required by Embarcadero LLC to acquire
the 27,988 shares of Common Stock reported in Item 5(a) was $234,289.00 and the
total amount of funds required by ILEX Alta Bio to acquire the 424,065 shares of
Common Stock reported in Item 5(a) was $3,549,852.00. Such funds were provided
by each entity's capital available for investment.
Item 4. Purpose of Transaction.
Alta BioPharma, Embarcadero LLC, and ILEX Alta Bio acquired
the Common Stock reported in Item 5(c) for investment only. Depending upon their
evaluation of the Company's investments and prospects, and upon future
developments (including, but not limited to, market for the Shares, the
effective yield on the Shares, availability of funds, alternative uses of funds,
and money, stock market and general economic conditions), each of the Reporting
Persons may from time to time purchase the Common Stock, dispose of all or a
portion of the Common Stock that it holds, or cease buying or selling Common
Stock. Any such additional purchases or sales of the Common Stock may be in open
market or privately negotiated transactions or otherwise.
On July 16, 1999, Alta BioPharma, Embarcadero LLC and ILEX
Alta Bio entered into a Stock Purchase Agreement (the "Stock Purchase
Agreement") with the Company pursuant to which Alta BioPharma, Embarcadero LLC
and ILEX Alta Bio acquired, for an aggregate purchase price of $10,000,000, a
total of 1,194,600 Shares of Common Stock. The entities also entered into a
Registration Rights Agreement.
On February 23, 2000, Alta BioPharma, Embarcadero LLC and ILEX
Alta Bio made distributions of 742,547, 27,988 and 424,065 shares of Common
Stock, respectively, to their partners or members without consideration.
Item 5. Interest in Securities of the Issuer.
(a) Alta BioPharma is the direct beneficial owner of 742,547
shares of Common Stock or approximately 3.5% of the shares deemed outstanding by
the Company (21,500,000) as of December 31, 1999. ILEX Alta Bio is the direct
beneficial owner of 424,065 shares of Common Stock or approximately 2.0% of the
shares deemed outstanding by the Company (21,500,000) as of December 31, 1999.
Embarcadero LLC is the direct beneficial owner of 27,988 Shares of Common Stock
or approximately 0.1% of the shares deemed outstanding by the Company
(21,500,000) as of December 31, 1999.
(b) Each entity has the power to direct the disposition of and
vote the stock held by it. By virtue of the relationships previously reported
under Item 2 of this Statement, Alta Management, Alta/Chase Management and Alta
Partners may be deemed to have indirect beneficial ownership of the shares owned
by such entities.
(c) On July 16, 1999 Alta BioPharma, ILEX Alta Bio, and
Embarcadero LLC acquired the Shares described in Item 3 of this Statement in a
privately negotiated transaction with the Company for aggregate consideration of
$6,215,859, $3,549,852 and $234,289, respectively.
<PAGE>
On February 23, 2000, Alta BioPharma made a distribution of
742,547 shares of Common Stock to its partners without consideration. On
February 23, 2000, Embarcadero LLC made a distribution of 27,988 shares of
Common Stock to its members without consideration. On February 23, 2000, ILEX
Alta Bio made a distribution of 424,065 shares of Common Stock to its members
without consideration.
Except as set forth above, neither the Reporting Persons nor
the Partners have effected any transaction in the Shares during the past 60
days.
(d) Alta BioPharma, ILEX Alta Bio and Embarcadero LLC each
have the right to receive dividends and proceeds from the sale of Common Stock
held by it. By virtue of the relationships reported in Item 2 of this Statement,
Alta Management, Alta/Chase Management and Alta Partners may be deemed to have
the power to direct the receipt of dividends and the proceeds from the sale of
the Common Stock held by each entity.
(e) On February 23, 2000, Reporting Persons ceased to be the
beneficial owner of more than five percent of the class of securities reported
herein.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
The ILEX Corporation Stock Purchase Agreement dated July 16,
1999 and The ILEX Corporation Registration Rights Agreement dated July 16, 1999
are hereby incorporated in their entirety by this reference.
Item 7. Material to be Filed as Exhibits.
Exhibit A: Joint Filing Statement.
Exhibit B: ILEX Oncology, Inc. Stock Purchase Agreement dated July 16,
1999, as previously submitted with the Schedule 13-D filed July 27, 1999
and incorporated herein by reference.
Exhibit C: ILEX Oncology, Inc. Management Rights Agreement dated July
16, 1999, as previously submitted with the Schedule 13-D filed July 27,
1999 and incorporated herein by reference.
Exhibit D: ILEX Oncology Inc. SBA Compliance Agreement dated July 16,
1999.
<PAGE>
Signature
<TABLE>
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: February 25, 2000
<CAPTION>
<S> <C>
ALTA PARTNERS ALTA BIOPHARMA PARTNERS, L.P.
By: Alta BioPharma Management Partners, LLC
By: By:
-------------------------------------- -----------------------------------------
Jean Deleage, President Daniel Janney, Managing Director
ALTA BIOPHARMA MANAGEMENT PARTNERS, LLC ALTA EMBARCADERO BIOPHARMA PARTNERS, LLC
By: By:
-------------------------------------- -----------------------------------------
Jean Deleage, Member Jean Deleage, Member
ILEX CHASE PARTNERS (ALTA BIO), LLC ALTA/CHASE BIOPHARMA MANAGEMENT, LLC
By: Alta/Chase BioPharma Management, LLC
By: By:
-------------------------------------- -----------------------------------------
Daniel Janney, Member Daniel Janney, Member
- ----------------------------------------- --------------------------------------------
Jean Deleage Guy Nohra
- ----------------------------------------- --------------------------------------------
Garrett Gruener Marino Polestra
- ----------------------------------------- --------------------------------------------
Daniel Janney Alix Marduel
</TABLE>
<PAGE>
EXHIBIT A
Joint Filing Statement
<TABLE>
We, the undersigned, hereby express our agreement that the attached
Schedule 13D is filed on behalf of each of us.
Date: February 25, 2000
<CAPTION>
<S> <C>
ALTA PARTNERS ALTA BIOPHARMA PARTNERS, L.P.
By: Alta BioPharma Management Partners, LLC
By: By:
-------------------------------------- -----------------------------------------
Jean Deleage, President Daniel Janney, Managing Director
ALTA BIOPHARMA MANAGEMENT PARTNERS, LLC ALTA EMBARCADERO BIOPHARMA PARTNERS, LLC
By: By:
-------------------------------------- -----------------------------------------
Jean Deleage, Member Jean Deleage, Member
ILEX JOLLA CHASE PARTNERS (ALTA BIO), LLC ALTA/CHASE BIOPHARMA MANAGEMENT, LLC
By: Alta/Chase BioPharma Management, LLC
By: By:
-------------------------------------- -----------------------------------------
Daniel Janney, Member Daniel Janney, Member
- ----------------------------------------- --------------------------------------------
Jean Deleage Guy Nohra
- ----------------------------------------- --------------------------------------------
Garrett Gruener Marino Polestra
- ----------------------------------------- --------------------------------------------
Daniel Janney Alix Marduel
</TABLE>
